期刊文献+

氘代沃替西汀氢溴酸盐的胚胎-胎仔发育毒性及伴随毒动学研究 被引量:6

The embryo-fetal development toxicity and toxicokinetics of deuterated Vortioxetine hydrobromide
原文传递
导出
摘要 目的考察灌胃给予氘代沃替西汀氢溴酸盐(DVH)对大鼠胚胎-胎仔发育的影响及其毒动学。方法将孕鼠随机分为溶媒组、阳性对照组(3.8mg·kg^-1注射用环磷酰胺)和DVH组(低、中、高剂量分别为8、24、80mg·kg^-1DVH),在妊娠GD6~GD15时灌胃给药,GD20时处死大鼠,记录各项指标,并检测母鼠的血药浓度以及DVH在孕鼠和胎仔(胎鼠)体内的组织分布。结果DVH呈现线性药动学特征。DVH及其羧基代谢产物可透过胎盘屏障,胎仔体内的脏器分布趋势与母体相近,DVH及其羧基代谢产物在胎仔肝脏中的含量最高、肾脏、肺脏次之,高剂量组出现的发育毒性可能与其相关。结论在试验条件下,24mg·kg^-1DVH未对孕鼠母体产生明显毒性,8mg·kg^-1DVH未对胎仔产生明显毒性。 OBJECTIVE To study the embryo -fetal development toxicity and toxicokinetics of deuterated Vortioxetine hydrobromide (DVH)via oral administration.METHODS Pregnant rats were divided into 5groups,treated with normal saline,cyclophosphamide for injection (3.8mg·kg^-1),and DVH (8,24,and 80mg·kg^-1DVH)respectivly and administrated orally in GD 6-GD 15.Rats were sacrificed on GD 20,and concentrations of DVH as well as its metabolites in plasma and tissues of both maternal and fetal were determined.RESULTS The toxcicokinetics of DVH are linear.The placental barrier was penetrated by DVH and metabolites,and the distribution in organs were similar in maternal and fetal,with the highest concentration in livers.Therefore might resulted in the development toxicity.CONCLUSION The no observed adverse effect level of DVH for maternal is 24mg·kg^-1,and for fetal is 8mg·kg^-1.
作者 蔡鸣 舒斌 邵卿 袁艳娟 张玉堂 乔红群 刘晶 CAI Ming;SHU Bin;SHAO Qing;YUAN Yanjuan;ZHANG Yutang;QIAO Hongqun;LIU Jing(Jiangsu Institute of Materia Medical,Nanjing,Jiangsu,210009P.R.China;Nanjing University of Technology,Nanjing,Jiangsu,211816P.R.China)
出处 《华西药学杂志》 CAS CSCD 2018年第6期594-598,共5页 West China Journal of Pharmaceutical Sciences
基金 江苏省政策引导类计划(产学研合作)——前瞻性联合研究项目(BY2016005-10)
关键词 氘代沃替西汀氢溴酸盐 大鼠 灌胃 胚胎-胎仔发育毒性 伴随毒动学 胎盘屏障 组织分布 代谢产物 Deuterated vortioxetine hydrobromide Rats Gavage Embryo -fetal development toxicity Concomitant toxicokinetics Placental barrier Organ distributions Metabolites
  • 相关文献

参考文献3

二级参考文献27

  • 1Bang-Andersen B,Ruhland T,See comment in PubMed Commonsbelowjorgensen M, et al. Discovery of l-[2-(2,4-dimethyl-phenylsulfanyl ) phenyl ] piperazine : a novel multimodal compound for the treatment of major depressive disorder[ J]. J Med Chem,2011,54(9) :3206-3221.
  • 2Waller JA,Chen F,Sanchez C. Vortioxetine promotes maturation of dendritic spines in vitro : a comparative study in hippocampal cultures [ J]. Neuropharmacology, 2016,103 : 143-154.
  • 3Chen F,Du Jardin KG,Waller JA,et al. Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus [ J ]. Eur Neuropsychopharmacol, 2016, 26(2) :234-245.
  • 4Smagin GN,Song D,Budac DP,et al. Histamine may contribute to vortioxetine,s procognitive effects ; possibly through an orexigenic mechanism [ J]. Prog Neuropsychopharmacol Biol Psychiatry, 2016,68(4) :25-30.
  • 5Du Jardin KG, Jensen JB,Sanchez C,et al. Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory : A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism [J]. Eur Neuropsychopharmacol, 2014,24(1) :160-171.
  • 6Mork A, Montezinho LP, Miller S, et al. Vortioxetine ( Lu AA21004) , a novel multimodal antidepressant, enhances memory in rats [J]. Pharmacol Biochem Behav, 2013, 105=41-50.
  • 7FDA. Vortioxetine[ EB/OL] . http://www.fda. gov/drugs/ scienceresearch/ researchareas/pharmacogenetics/ ucm397142. htm,2015-04-21.
  • 8Chen G,Lee R, Hojer AM,et al. Pharmacokinetic drug interactions involving vortioxetine (LuAA21004),a multimodal antidepressant[ J]. Clin Drug Investig, 2013,33(10) :727-736.
  • 9Spina E,Santoro V. Drug interactions with vortioxetine, a new multimodal antidepressant [ J ]. Riv Psichiatr, 2015 , 50(5) :210-215.
  • 10Gibb A,Deeks ED. Vortioxetine: first global approval[ J]. Drugs, 2014, 74( 1) : 135-145.

共引文献10

同被引文献15

引证文献6

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部